Casdin Capital, LLC is a New York-based research investment firm focused on the innovations in molecular medicine currently reshaping Life Sciences and healthcare. Founded in 2011, and with an eye to long-term returns and disruptive technologies, Casdin Capital is an expert working with experts, benefiting from its position at the crossroads of the science and investment communities. As trusted investor-partners in both private and public companies, we collaborate with industry leaders to fuel their visions, adding energy, insight, and experience to our over $2.4 billion under management. As we push into new markets and new developments, we stick to our core principles—deep analysis, intellectual honesty, hard work and partnerships with the best people. That approach translates to thousands of conversations with the developers of the drugs, diagnostics, tools and technologies that power this industry, and the data assets and service companies that support the research and product commercialization. In our first ten years, Casdin’s hands-on approach and on-the-ground experience led us to identify the key innovations that are spurring today’s remarkable industry growth. Today, we remain just as focused. Life Sciences and Casdin Capital are just getting started.
Looking for a particular Casdin Capital, LLC employee's phone or email?
The Casdin Capital, LLC annual revenue was $8 million in 2026.
Alexandria Fisk is the COO of Casdin Capital, LLC.
42 people are employed at Casdin Capital, LLC.
Casdin Capital, LLC is based in New York, New York.
The NAICS codes for Casdin Capital, LLC are [523, 52, 5239].
The SIC codes for Casdin Capital, LLC are [67, 679].